Immunovant CMO Michael Geffner departs; consulting through April 2026

Immunovant, Inc.

Michael Geffner, M.D., M.B.A., ceased as Chief Medical Officer effective Nov 21, 2025.
Departure is part of R&D leadership restructuring under CEO Eric Venker.
Severance per existing employment agreement; consulting services through April 30, 2026.
Outstanding equity awards continue vesting during consulting period; accelerated vesting on change in control.
Option exercise period extended to nine months after consulting ends or original expiration, whichever earlier.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.